Skip to: Content
Skip to: Site Navigation
Skip to: Search

MONDAY, NOVEMBER 23, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter


0

Ovarian Cancer Test 'Premature,' Critics Worry

Early screening's false positives may cause unneeded surgeries

Share

(Newser) – Though a new ovarian cancer test gives hope that the 21,000 new cancer cases expected this year may be detected at a treatable stage, the FDA is worried OvaSure may do more harm than good, the New York Times reports. If the unregulated test detects cancer where there isn't any—as expected in 0.6% of cases—some women may have unnecessary surgeries.

"You've got industry trying to capitalize on fear," one doc says of the $220 test. But others counter that ovaries are already being removed unnecessarily in women who are at high risk for cancer, and that OvaSure could lessen such instances. The cancer claims 15,000 lives a year and has symptoms that can be mistaken for several other conditions.

The FDA is concerned that OvaSure, an early detection test for ovarian cancer, has not been properly tested.
The FDA is concerned that OvaSure, an early detection test for ovarian cancer, has not been properly tested.   (KRT Photos)
Though the blood test has a margin of error, some doctors say OvaSure will lessen instances of unnecessary surgeries.
Though the blood test has a margin of error, some doctors say OvaSure will lessen instances of unnecessary surgeries.   (KRT Photos)
« Prev« Prev | Next »Next » Slideshow

You’ve got industry trying to capitalize on fear. We’d all love to see a screening test for ovarian cancer, but OvaSure is very premature. - Dr. Andrew Berchuck, director of gynecologic oncology at Duke

« Prev« Prev | Next »Next » Slideshow
0 comments
VIEWING:
 
LEAVE A
COMMENT
Comment Policy
Facebook ConnectPost this comment to Facebook?

After connecting you will have the option to post your comment on your Facebook profile.